CLINICAL RESEARCH: VASCULAR MEDICINE
Vascular Effects of Apelin In Vivo in Man
Alan G. Japp, MRCP*,*,
Nicholas L. Cruden, PhD*,
David A.B. Amer*,
Vivienne K.Y. Li, BSc*,
Ewan B. Goudie, BSc*,
Neil R. Johnston, MSc*,
Sushma Sharma, PhD ,
Ilene Neilson, BSc ,
David J. Webb, MD, FRCP*,
Ian L. Megson, PhD ,
Andrew D. Flapan, MD, MRCP and
David E. Newby, PhD, FRCP*
* Centre for Cardiovascular Science, University of Edinburgh, Chancellor's Building, Edinburgh, United Kingdom
Department of Diabetes, UHI Millennium Institute, Inverness, United Kingdom
Department of Cardiology, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Manuscript received November 12, 2007;
revised manuscript received March 26, 2008,
accepted June 3, 2008.
* Reprint requests and correspondence: Dr. Alan G. Japp, Centre for Cardiovascular Science, The University of Edinburgh, Chancellor's Building, Edinburgh, EH16 4SB, United Kingdom (Email: alan.japp{at}ed.ac.uk).
Objectives: This study was designed to establish the direct vascular effects of apelin in vivo in man.
Background: Apelin is the endogenous ligand for the previously orphaned G-protein–coupled receptor, APJ. This novel pathway is widely expressed in the cardiovascular system and is emerging as an important mediator of cardiovascular homeostasis. In pre-clinical models, apelin causes venous and arterial vasodilation.
Methods: Vascular effects of apelin were assessed in 24 healthy volunteers. Dorsal hand vein diameter was measured by the Aellig technique during local intravenous infusions (0.1 to 3 nmol/min) of apelin-36, (Pyr1)apelin-13, and sodium nitroprusside (0.6 nmol/min). Forearm blood flow was measured by venous occlusion plethysmography during intrabrachial infusions of apelin-36 and (Pyr1)apelin-13 (0.1 to 30 nmol/min) and subsequently in the presence or absence of a "nitric oxide clamp" (nitric oxide synthase inhibitor, L-N
G-monomethylarginine [8 µmol/min], coinfused with nitric oxide donor, sodium nitroprusside [90 to 900 ng/min]), or a single oral dose of aspirin (600 mg) or matched placebo.
Results: Although sodium nitroprusside caused venodilation (p < 0.0001), apelin-36 and (Pyr1)apelin-13 had no effect on dorsal hand vein diameter (p = 0.2). Both apelin isoforms caused reproducible vasodilation in forearm resistance vessels (p < 0.0001). (Pyr1)apelin-13–mediated vasodilation was attenuated by the nitric oxide clamp (p = 0.004) but unaffected by aspirin (p = 0.7).
Conclusions: Although having no apparent effect on venous tone, apelin causes nitric oxide–dependent arterial vasodilation in vivo in man. The apelin-APJ system merits further clinical investigation to determine its role in cardiovascular homeostasis.
Key Words: apelin APJ receptor endothelium vasodilator
|
Abbreviations and Acronyms
| | ANOVA = analysis of variance | | APJ = apelin receptor | | AUC = area under the curve | | DHV = dorsal hand vein | | FBF = forearm blood flow | | NO = nitric oxide | | SNP = sodium nitroprusside |
|
This article has been cited by other articles:

|
 |

|
 |
 
R. Rastaldo, S. Cappello, A. Folino, G. N. Berta, A. E. Sprio, G. Losano, M. Samaja, and P. Pagliaro
Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia
Am J Physiol Heart Circ Physiol,
June 1, 2011;
300(6):
H2308 - H2315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Chandra, H. Razavi, J. Kim, R. Agrawal, R. K. Kundu, V. de Jesus Perez, R. T. Zamanian, T. Quertermous, and H. J. Chun
Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary Hypertension
Arterioscler Thromb Vasc Biol,
April 1, 2011;
31(4):
814 - 820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Iturrioz, R. Gerbier, V. Leroux, R. Alvear-Perez, B. Maigret, and C. Llorens-Cortes
By Interacting with the C-terminal Phe of Apelin, Phe255 and Trp259 in Helix VI of the Apelin Receptor Are Critical for Internalization
J. Biol. Chem.,
October 15, 2010;
285(42):
32627 - 32637.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. L. Pitkin, J. J. Maguire, T. I. Bonner, and A. P. Davenport
International Union of Basic and Clinical Pharmacology. LXXIV. Apelin Receptor Nomenclature, Distribution, Pharmacology, and Function
Pharmacol. Rev.,
September 1, 2010;
62(3):
331 - 342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Barnes, A. G. Japp, and D. E. Newby
Translational promise of the apelin-APJ system
Heart,
July 1, 2010;
96(13):
1011 - 1016.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Japp, N. L. Cruden, G. Barnes, N. van Gemeren, J. Mathews, J. Adamson, N. R. Johnston, M. A. Denvir, I. L. Megson, A. D. Flapan, et al.
Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure
Circulation,
April 27, 2010;
121(16):
1818 - 1827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Yue, H. Jin, M. Aillaud, A. C. Deng, J. Azuma, T. Asagami, R. K. Kundu, G. M. Reaven, T. Quertermous, and P. S. Tsao
Apelin is necessary for the maintenance of insulin sensitivity
Am J Physiol Endocrinol Metab,
January 1, 2010;
298(1):
E59 - E67.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. J. Maguire, M. J. Kleinz, S. L. Pitkin, and A. P. Davenport
[Pyr1]Apelin-13 Identified as the Predominant Apelin Isoform in the Human Heart: Vasoactive Mechanisms and Inotropic Action in Disease
Hypertension,
September 1, 2009;
54(3):
598 - 604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A.P. Weir, K. S. Chong, J. R. Dalzell, C. J. Petrie, C. A. Murphy, T. Steedman, P. B. Mark, T. A. McDonagh, H. J. Dargie, and J. J.V. McMurray
Plasma apelin concentration is depressed following acute myocardial infarction in man
Eur J Heart Fail,
June 1, 2009;
11(6):
551 - 558.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|